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Circulating endothelial progenitor cells (EPCs) partici-pate in vasculogenesis after incorporation into regions 
of neovascularization and differentiation into endothelial 
cells (ECs) and promote angiogenesis by the production of 
angiogenic growth factors.1–3 Thus, EPC-induced vasculogen-
esis provides a novel therapeutic approach for patients with 
heart and limb ischemia.4,5 To achieve efficient and therapeuti-
cally useful EPC grafting, various trials have tested local EPC 
delivery, promotion of EPC mobilization, enhancement of 
EPC function, and in vitro EPC expansion.6–9 Select cytokines 
trigger rapid EPC expansion in culture systems and improve 
EPC angiogenic potency, which are essential for advancing 
the grafting efficacy of therapeutic EPCs.4,7,10 For example, 
local administration of stromal-derived factor-1 induces 
neovascularization after EPC transplantation by recruiting 
EPCs to pre-existing vessels and increasing their incorpora-
tion into the developing vasculature.8,11 As well, ex vivo EPC 
priming with stromal-derived factor-1 significantly enhances 
subsequent EPC transplantation efficacy.12 EPC maturation is 
also enhanced in the presence of cytokines and growth fac-
tors, such as vascular endothelial growth factor (VEGF)-A, 
fibroblast growth factor-2, and insulin-like growth factor.13 
CD34+ EPC→EC differentiation is induced by VEGF, which 
increases bone marrow–derived EPC engraftment in the 
developing vasculature of neonatal mice.7 However, EPC biol-
ogy is complex, and our understanding of the precise mecha-
nisms that regulate EPC differentiation is limited. To improve 
the focus and safety of clinical trials using EPCs, we need to 
identify the angiogenic factors that enhance EPC differentia-
tion and functional incorporation into the neovasculature of 
ischemic tissues.
The transforming growth factor-β (TGF-β) superfamily 
exerts multiple effects on most cell types, depending on the 
cellular and environmental contexts. Members of the TGF-β 
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family have been linked to vascular formation and the modula-
tion of vascular inflammatory responses and remodeling.14–16 
The TGF-β family also plays important roles in the self-
renewal, maintenance of pluripotency, and differentiation of 
embryonic stem cells (ES).17,18 Specific ligands induce TGF-β 
signaling by forming a heterotetrameric complex of type I and 
II receptors, which subsequently initiate Smad phosphorylation 
in a type I receptor– and cell type–dependent fashion.15 Among 
TGF-β type I receptors, activin receptor-like kinase-1 (ALK1) 
is specifically expressed in blood vessels during embryogene-
sis14 and adult stages.19 In addition, ALK1 mutations have been 
linked to type II hereditary hemorrhagic telangiectasia, which 
is characterized by hemorrhages and vascular malformations.16 
Recent studies have revealed that the ubiquitously expressed 
type I receptor ALK5 inhibits EC migration and prolifera-
tion, whereas EC-restricted ALK1 promotes both processes 
after stimulation with TGF-β1.20,21 Interestingly, recent studies 
have also shown that bone morphogenetic protein 9 (BMP9) 
binds with high affinity to ALK1 in ECs.22,23 BMP9 circulates 
in human plasma at high concentrations and helps to maintain 
the maturation status of blood vessels.24,25 However, the precise 
function of BMP9 in vascular physiology remains unclear.
In this study, we evaluated the ALK1 expression in EPCs 
and then investigated the role of its potential ligand BMP9 in 
regulating EPC differentiation and function. We likewise ana-
lyzed the ALK1 and Smad1/5 pathways to explore the under-
lying mechanisms. To investigate the possible implication of 
BMP9 in EPC-mediated neovascularization further, we evalu-
ated the therapeutic efficiency of the administration of BMP9 
with EPCs in a mouse hindlimb ischemia model. Our resulting 
observations revealed a novel role for BMP9/ALK1 in EPC-
mediated neovascularization, and suggested that BMP9 may 
serve as a viable new target for limb ischemia.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Identification of Angiogenic Regulators 
During EPC Differentiation
EPCs were isolated from human cord blood by density gradi-
ent and cultured on fibronectin-coated plates (Figure IA in the 
online-only Data Supplement). We confirmed EPC identity 
by the uptake of DiI-labled acetylated low-density lipopro-
tein (Figure IB in the online-only Data Supplement). After 
7 days of cell culture, the EPCs formed distinct colonies on 
fibronectin-coated dishes (Figure IC in the online-only Data 
Supplement). The EC-like colony-forming EPCs differenti-
ated into outgrowing EPCs26,27 (Figure ID in the online-only 
Data Supplement) that expressed the EC marker VE-cadherin 
(Figure IE in the online-only Data Supplement) and exhibited 
endothelial phenotypes including tube formation (Figure IF in 
the online-only Data Supplement). Furthermore, we evaluated 
the expression of multiple previously described markers for 
various cell types,28 including CXCR4 (EPCs), CD45 (hema-
topoietic cells), and CD31 and kinase insert domain receptor 
(KDR; ECs; Figure IG in the online-only Data Supplement).
To understand the molecular signatures associated with 
the differentiation of EPCs, we generated mRNA expression 
profiles at days 5, 7, 9, 13, and 17 of EPC differentiation using 
the HumanHT-12 v3 Expression BeadChip Kit, which uses 
48 000 genome-wide probes. First, we identified 8284 dif-
ferentially expressed genes with >1.5-fold differences when 
compared with undifferentiated, early EPCs (day 5). These 
8284 differentially expressed genes were categorized into 76 
clusters based on gene function (Table I in the online-only 
Data Supplement). Among these, 14 clusters were defined as 
major patterns during EPC differentiation, given the large clus-
ter size (>50 genes) and their consistent expression patterns 
(Figure 1A). We then performed enrichment analysis of the 
gene ontology biological processes and Kyoto Encyclopedia 
of Genes and Genomes pathway database searches for the 
14 gene clusters (Figure 1B) using DAVID (The Database 
for Annotation, Visualization and Integrated Discovery) 
Functional Annotation Bioinformatics Microarray Analysis 
software.29 Most of the immune response-related genes were 
expressed at early differentiation stages and continuously 
decreased in expression as endothelial differentiation pro-
gressed, whereas expression of angiogenic functional genes 
related to wound healing and actin cytoskeleton increased 
concurrently with EPC→EC maturation (Figure 1B). 
Furthermore, EPC→EC differentiation also activated sig-
naling pathways involved in angiogenesis,30–33 including the 
TGF-β, BMP, Notch, and integrin signaling pathways.
Among the 14 clusters, we focused on the 7 upregulated 
clusters that apparently contributed to promoting EPC differ-
entiation. We then identified 493 potential angiogenic regula-
tors (Table II in the online-only Data Supplement) that could 
contribute to EPC differentiation by selecting hub-like mol-
ecules with a significant (P<0.01) number of interactors in 
the 7 upregulated clusters based on the interactome data.34–38 
We then performed enrichment analysis of the gene ontology 
biological processes and Kyoto Encyclopedia of Genes and 
Genomes pathways for the 493 potential angiogenic regula-
tors (Table). Interestingly, these regulators included 24 com-
ponents involved in TGF-β signaling and 47 components 
involved in the regulation of the actin cytoskeleton that most 
closely interacted with the TGF-β signaling pathway (Figure 
II in the online-only Data Supplement). After reconstruction 
of the network model delineating the functional roles of TGF-
β signaling using the 24 and 47 components, we found that 
the expression of ALK1, a TGF-β type 1 receptor, was most 
Nonstandard Abbreviations and Acronyms
ALK1 activin receptor-like kinase 1
BMP9 bone morphogenetic protein 9
CA-ALK1 constitutively active ALK1
EC endothelial cell
EPC endothelial progenitor cell
ES embryonic stem cells
hEPCs human EPCs
HUVEC human umbilical vein cell
KDR kinase insert domain receptor
TGF-β transforming growth factor-β
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notably changed during EPC differentiation (Figure II in the 
online-only Data Supplement).
Expression of ALK1 in EPCs and 
Identification of BMP9
First, we determined the expression patterns of key ligands 
and receptors in the TGF-β signaling pathway to evaluate 
their correlations with the network model. We obtained sam-
ples from early EPCs and endothelial outgrowth cells, and the 
expression levels of TGF-β family members were evaluated 
in each respective stage. As confirmed by quantitative reverse 
transcriptase-polymerase chain reaction and flow cytometry 
analysis, ALK1 expression was significantly upregulated dur-
ing EPC→EC differentiation (Figure 1C and 1D). Conversely, 
the expression of ALK5 was decreased. Previous reports have 
indicated that ALK1 is important in blood vessel formation 
during embryogenesis14 and adult stages,19 and that mice 
genetically deficient for ALK1 exhibit severe vascular malfor-
mation.16 This suggests the possibility that activation of ALK1 
signaling by specific ligands contributes to the differentiation 
and homing of stem/progenitor cells that participate in new 
vessel formation. BMP9, a high-affinity ligand for ALK1,23,39 
demonstrated a similar expression pattern, which was consis-
tent with the increased expression of ALK1 (Figure 1C).
Figure 1. Identification of activin receptor-like kinase 1 (ALK1) during endothelial progenitor cell (EPC)→endothelial cell (EC) differentia-
tion. Major clusters of gene expression change and associated cellular processes during EPC→EC differentiation. A, Fourteen major 
clusters (C1–2, C5, C14, C25, C34, C37, C39, C42, C51, C63, C72, and C75–76) of the genes showing differential expression during 
EPC differentiation. Gene expression change during EPC differentiation (day 7 to day 17) is shown as log2-fold-changes using day 5 as a 
control. Red and green colors indicate up- and downregulation, respectively. (positive and negative log2-fold-changes; see the color bar). 
B, Gene ontology biological process and Kyoto Encyclopedia of Genes and Genomes pathways represented by the genes in individual 
clusters. Color gradient indicates –log10(P), where P is the enrichment P value obtained from the DAVID (The Database for Annotation, 
Visualization and Integrated Discovery) software (see the color bar). C, Expression of ALK1 and other transforming growth factor (TGF)-β 
family genes measured by a quantitative reverse transcriptase-polymerase chain reaction analysis. The transcript levels were normalized 
to GAPDH mRNA levels. D, Phase-contrast figures showing EPC morphology at each stage. Scale bars, 150 μm. ALK1 expression was 
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Effect of BMP9 on EPC→EC 
Differentiation In Vitro
Next, we evaluated whether BMP9 actively participated in 
EPC→EC differentiation. We treated EPC cultures with BMP9 
every 2 days, starting 7 days after the initial EPC isolation. 
endothelial outgrowth cells morphology began to appear on 
day 15 in BMP9-treated EPCs when compared with day 21 in 
unstimulated control EPC cultures (Figure 2A–2C). We then 
characterized differentiated colonies by assessing EC marker 
expression. We performed quantitative reverse transcriptase-
polymerase chain reaction for CD31, KDR, and CD144 
(Figure 2D) and further confirmed the results by fluorescence-
activated cell sorter analysis (Figure 2E). BMP9 stimulation 
led to significant increases in the expression levels of CD31, 
KDR, and CD144 (Figure 2D and 2E), which suggested that 
BMP9 stimulation acts on EPCs to promote EC differentiation.
Effect of BMP9 on EPC Functionality In Vitro
EPC homing is a multistep process that involves initial cell 
adhesion to the microvascular wall, transmigration, and tis-
sue invasion.40 The EPC homing capacity enhances the func-
tional integration of injected EPCs used in cell-based therapies. 
Therefore, we examined the effect of BMP9 on EPC migration 
using modified Boyden chamber assays. When compared with 
unstimulated EPCs, BMP9 stimulation increased EPC migra-
tory capacity to a level that approached the extent obtained after 
stimulation with VEGF (Figure 2F), a known EPC chemokine.41
EPC adhesion to the extracellular matrix and mature ECs 
is important for regenerative activity during vasculogenesis.40 
Therefore, we examined the effect of BMP9 on EPC adhesion 
to fibronectin and human umbilical vein cells (HUVECs) 
using VEGF as a positive control,41 and discovered that 
BMP9 increased EPC adhesion to fibronectin (Figure 2G) and 
HUVECs (Figure 2H). A prior report indicated that integrins 
are important for the homing of transplanted hematopoietic 
stem cells to bone marrow.42 Thus, we investigated the contri-
bution of α5- and β1-integrins, which have important roles in 
EPC adhesion and migration.42 Interestingly, BMP9 treatment 
(10 ng/mL) for 10 days increased EPC integrin α5 and β1 
mRNA expression levels (Figure 2I).
To gain additional insight into the effect of BMP9 on EPC 
angiogenic properties, we performed Matrigel angiogenesis 
assays. The coculturing of HUVECs with EPCs on a Matrigel 
matrix led to tubule network formation and the ability of EPCs 
to integrate into vascular networks in vitro.9 When we cocul-
tured HUVECs with EPCs, BMP9 stimulated greater tubule 
network formation (Figure 2J) as determined by tube length 
(Figure 2K) and number (Figure 2L). Furthermore, the num-
ber of EPCs incorporated into EPC/HUVEC tubule networks 
per total tubule area was significantly higher when cocultures 
were stimulated with BMP9 (Figure 2M).
Finally, to explore the effect of BMP9 stimulation on EPC 
viability, we measured cellular ATP levels after treatment with 
different doses of BMP9 during starvation for 48 hours, but 
no differences in EPC viability after BMP9 treatment were 
detected (Figure III in the online-only Data Supplement). 
Collectively, the data suggested that BMP9 increases EPC 
capacity in vitro by enhancing both migratory and adhesive 
activities rather than by affecting EPC viability.
Blocking Effect of ALK1 on BMP9-Induced 
EPC→EC Differentiation In Vitro
Having demonstrated that EPCs express ALK1 (Figure 1C 
and 1D), we investigated the role of ALK1 on BMP9-induced 
EPC differentiation. The transfection of EPCs with lentiviral 
constructs encoding constitutively active ALK1 (CA-ALK1) 
or dominant-negative ALK1 constructs resulted in increased 
ALK1 protein expression when compared with EPCs that 
were mock-transfected with virus alone (Figure IVB in the 
online-only Data Supplement). When we replenished the EPC 
media containing 10 ng/mL BMP9 every 2 days for 25 days, 
CA-ALK1–transfected EPCs exhibited EC-like morphol-
ogy earlier than either dominant-negative ALK1– or mock-
transfected EPCs (Figure 3A; Figure IVA in the online-only 
Data Supplement). The increase in the number of differen-
tiated colonies was also greater in CA-ALK1–transfected 
EPCs than in dominant-negative ALK1– or mock-transfected 
EPCs (Figure 3B). As well, differentiated colonies were 
determined by EC using quantitative reverse transcriptase-
polymerase chain reaction for CD31, KDR, and CD144 
(Figure 3C; Figure IVC and IVD in the online-only Data 
Supplement). Taken together, the data suggested that BMP9 
contributes to EPC→EC differentiation through ALK1 sig-
naling. Interestingly, when we cultured transfected EPCs 
without BMP9, we noted an increase in the number of differ-
entiated colonies in CA-ALK1–transfected EPCs (Figure IVE 
in the online-only Data Supplement), but to a lesser extent 
than BMP9-treated EPCs. The results indicated that ALK1 
Table.  GOBP and KEGG Pathways Enriched By Up-Pattern 
Regulators
GOBP and KEGG Pathways Count P Value
Focal adhesion 86 1.25E−47
Cell cycle 118 2.62E−44
Regulation of apoptosis 102 4.97E−31
ECM-receptor interaction 45 1.97E−29
Regulation of cell proliferation 85 6.06E−21
TGF-β signaling pathway 33 7.12E−16
ErbB signaling pathway 33 7.12E−16
Cell adhesion 66 2.94E−13
DNA repair 37 1.66E−11
Chromosome organization 47 5.87E−10
Embryonic development ending  
in birth
37 1.62E−09
Vasculature development 30 1.40E−08
Apoptosis 24 1.62E−08
p53 signaling pathway 21 1.99E−08
Neuron differentiation 40 7.13E−08
Wnt signaling pathway 31 1.33E−07
Regulation of actin cytoskeleton 38 2.20E−07
Chemokine signaling pathway 34 5.73E−07
ECM indicates extracellular matrix; ErbB, erythroblastic leukemia viral 
oncogene homolog; GOBP, gene ontology biological processes; KEGG, Kyoto 
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activation is required for EPC→EC differentiation, and that 
BMP9 may act endogenously through ALK1 in EPCs.
Blocking Effect of ALK1 on BMP9-Induced 
Angiogenic EPC Activity In Vitro
To investigate whether ALK1 affects BMP9-induced EPC 
angiogenic activity, we used a soluble chimeric ALK1 pro-
tein (hALK1-Fc) to competitively inhibit exogenous BMP9 
signaling.43 Treatment with hALK1-Fc reduced BMP9-
induced Smad1/5/8 phosphorylation in EPCs to basal levels 
(Figure 3D) and decreased BMP9-induced EPC migration and 
adhesion (Figure 3E and 3F). In addition, hALK1-Fc treat-
ment abrogated BMP9-induced increases in tube length and 
number (Figure VA–VC in the online-only Data Supplement) 
and decreased the number of EPCs incorporated into the ves-
sel-like structures (Figure VD and VE in the online-only Data 
Supplement). These data suggested that ALK1 activation is 
related to the BMP9-induced angiogenic abilities of EPCs.
To demonstrate that the role of BMP9 in tube formation 
is primarily because of the effect of BMP9 on EPCs rather 
than on HUVECs, we primed EPCs with BMP9 for 24 hours 
before performing Matrigel angiogenesis assays. The cocul-
turing of BMP9-primed EPCs with HUVECs on a Matrigel 
matrix resulted in increased tubule network formation 
(Figure 3G–3J). When EPCs were pretreated with hALK1-Fc, 
HUVECs cocultured with BMP9-primed EPCs on a Matrigel 
matrix exhibited reduced tubule formation as measured by 
length and number (Figure 3H and 3I). We found that hALK1-
Fc pretreatment also reduced the number of BMP9-primed 
EPCs incorporated into tubules (Figure 3J). Collectively, our 
results demonstrated that the effect of BMP9 on tubule net-
work formation is exerted solely on EPCs and is mediated by 
ALK1/Smad signaling.
Enhanced Neovascularization by Local 
Injection of BMP9 and EPCs in a 
Mouse Hindlimb Ischemia Model
Finally, we investigated whether injecting EPCs with BMP9 
would enhance neovascularization in vivo using a mouse 
hindlimb ischemia model. After inducing ischemia by excis-
ing 1 femoral artery, athymic nude mice received an intra-
muscular injection of human EPCs (hEPCs), with or without 
BMP9, in the lower calf muscle of the ischemic limb. As addi-
tional controls, other groups of mice with hindlimb ischemia 
were injected with vehicle or BMP9 alone. Blood perfusion in 
the ischemic and nonischemic hindlimbs was assessed using 
laser-Doppler imaging. Mice coinjected with EPCs and BMP9 
exhibited significantly enhanced recovery of hindlimb blood 
Figure 2. Bone morphogenetic protein 9 (BMP9) 
induces endothelial progenitor cell (EPC)–endothelial 
cell (EC) differentiation and endothelial progenitor cells 
(EPCs) angiogenic function in vitro. A–C, Morphologi-
cal assessment of the differentiation of EPCs on day 
17 using phase-contrast microscopy (A). Dashed lines 
indicate endothelial outgrowth cell colony. Scale bars, 
150 µm. Quantitative analysis of the differentiation rate 
(B) and the number of colonies (C). *P<0.05 vs control. 
D and E, After exposure of EPCs to BMP9 (10 ng/mL) 
for 17 days, mRNA and protein levels of the endothelial 
markers CD31, KDR, and CD144 were assessed by 
quantitative reverse transcriptase-polymerase chain 
reaction (RT-PCR) (D) and fluorescence-activated cell 
sorter analysis (E). ***P<0.001 vs control. F, D7-EPC 
migration assays were performed using a modified Boy-
den chamber containing BMP9 (10 ng/mL) or vascular 
endothelial growth factor (VEGF; 20 ng/mL) in the lower 
chamber. Cell migration was assessed by counting cells 
in 8 random fields. ***P<0.001 vs control. G and H, Cal-
cein AM–labeled D7-EPCs were seeded onto fibronec-
tin (G) or human umbilical vein cell (HUVEC; H)–coated 
96-well plates with BMP9 (10 ng/mL) or VEGF (20 ng/
mL). After 1 hour in culture, wells were gently washed, 
and adhesion was quantified by counting attached 
EPCs using fluorescence microscopy. ***P<0.001, 
**P<0.01 vs control. I, EPCs were cultured with or with-
out BMP9 (10 ng/mL), and integrin α5 and β1 mRNA 
levels were determined by RT-PCR. Densitometric band 
analyses are quantified using ImageJ software and are 
presented as the relative ratio of ITGA5 or ITGB1 to 
GAPDH. The relative ratio in untreated control cells is 
arbitrarily presented as 1.00 (bottom). J–M, D7-EPCs 
stained with calcein AM were cocultured with HUVECs 
atop Matrigel-coated 24-well plates in low-serum (1%) 
media with or without BMP9 (10 ng/mL). Representative 
images of complete tube formation (J, original magnifi-
cation ×40 [top] and ×100 [bottom]), and quantification 
of tube length (K), tube number (L), and the number of 
EPCs that were incorporated into tube-like structures 
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perfusion when compared with mice that were treated with 
EPCs, vehicle, or BMP9 only (Figure 4A and 4B). Four weeks 
after injection, the group injected with vehicle only exhibited 
extensive necrosis of the ischemic hindlimb, which resulted in a 
high rate of limb loss and necrosis (Figure VI in the online-only 
Data Supplement). Intramuscular injection of EPCs reduced the 
rate of limb loss when compared with the vehicle or BMP9-
only injection groups, and the effects of the coadministration 
of EPCs and BMP9 on limb salvage remained significantly 
enhanced (Figure 4A and 4B). Next, we examined the histol-
ogy of hindlimb skeletal muscle sections from mice euthanized 
28 days after EPC injection. Histological examinations revealed 
significantly more CD31-positive capillary ECs in muscle sec-
tions from mice that received EPCs and BMP9 versus mice that 
were injected with EPCs alone or with vehicle or BMP9 only 
(Figure 4C and 4D). Collectively, the data indicated that blood 
flow recovery and new vessel formation in ischemia-damaged 
muscle were increased by local injection of EPCs with BMP9.
To evaluate the impact of BMP9 on EPC-mediated revas-
cularization further, we also compared the effects of BMP9-
primed EPCs on neovascularization in the mouse hindlimb 
ischemia model. Cord blood–derived EPCs primed for 24 
hours with or without BMP9 were intramuscularly injected 
into ischemic limbs. The injection of BMP9-primed EPCs 
improved limb perfusion when compared with vehicle-primed 
EPCs (Figure 4E and 4F). Histologically, we also observed 
more capillaries in ischemic limbs from mice that received 
BMP9-primed EPCs (Figure 4G and 4H). Hence, our results 
conclusively demonstrated that BMP9 enhances the effects of 
injected EPCs on increased blood perfusion and vessel density 
in ischemic hindlimbs in mice.
Engraftment of Transplanted EPCs With BMP9 
Into Vascular Structures in Ischemic Limbs
To determine the contribution of EPCs implanted with BMP9 
on neovascularization, we assessed EPC incorporation. The 
presence of hEPCs in ischemic limbs after transplantation 
was assessed using reverse transcriptase-polymerase chain 
reaction analysis of human GAPDH, and the results revealed 
that GAPDH was specifically expressed in the EPC-injected 
group (Figure 5A). We verified EPC engraftment using DiI-
acLDL–labeled (Figure 5B; Figure VIIA in the online-only 
Data Supplement) and calcein AM–labeled EPCs (Figure 5C–
5E; Figure VIIB in the online-only Data Supplement) and 
performed immunohistochemical labeling for human nuclear 
antigen (Figure 5D). The formation of capillary networks 
was confirmed by CD31-positive ECs in ischemic muscles 
(Figure 5B and 5C, arrowheads). Furthermore, numerous 
hEPCs were detected and frequently colocalized with CD31-
positive mouse ECs in BMP9/EPC-injected mice (Figure 5B 
Figure 3. Bone morphogenetic protein 9 (BMP9)–
induced endothelial progenitor cell (EPC) differen-
tiation and vascularization is regulated by activin 
receptor-like kinase 1 (ALK1) signaling in vitro. 
A–C, D7-EPCs transfected with lentivirus encoding 
mock, constitutively active (CA)-ALK1 or dominant 
negative (DN-ALK1). We treated transfected EPCs 
with or without BMP9 (10 ng/mL) every 2 days for 
25 days. Quantitative analysis of the differentia-
tion rate (A) and the number of colonies (B). After 
exposure of EPCs to BMP9 (10 ng/mL) for 20 days, 
mRNA levels of the endothelial marker CD144 were 
assessed by quantitative reverse transcriptase-
polymerase chain reaction (C). D, Before 1-hour 
treatment with hFc-ALK1 (10 µg/mL), EPCs were 
incubated with BMP9 (10 ng/mL) for 2 hours. 
BMP9-induced Smad 1/5/8 phosphorylation was 
determined by Western blotting. E, D7-EPC migra-
tion assays were performed using a modified Boy-
den chamber with or without BMP9 (10 ng/mL) and 
hFc-ALK1 (A1; 10 µg/mL) in the lower chamber. Cell 
migration was assessed by counting cells in eight 
random fields. F, Calcein AM–labeled D7-EPCs 
were seeded onto fibronectin-coated 96-well plates 
with or without BMP9 (10 ng/mL) and hFc-ALK1 
(A1; 10 µg/mL). After 1 hour in culture, wells were 
gently washed, and adhesion was quantified by 
counting attached EPCs using fluorescence micros-
copy. G–J) We pretreated D7-EPCs with or without 
hFc-ALK1 (A1; 10 µg/mL) for 1 hour before priming 
with BMP9 (10 ng/mL). BMP9-primed EPCs and 
HUVECs were seeded into Matrigel-coated wells. 
Representative images of complete tube formation 
(original magnification ×40 [G]) and quantification 
of tube length (H), tube number (I), and the number 
of EPCs incorporated into tube-like structures (J). 
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and 5C, arrows). Human nuclear antigen staining with CD31 
confirmed the presence of blood vessels comprised trans-
planted hEPCs (arrows) and mouse ECs (Figure 5D). In addi-
tion, incorporated calcein AM–labeled EPCs were stained 
with KDR, which revealed endothelial lineage 1 month after 
EPC injection (Figure 5E). Taken together, BMP9 helped the 
transplanted hEPCs to successfully engraft into mouse tis-
sue and subsequently induced vascular network formation by 
improving both the incorporation of EPCs into the vasculature 
and the EPC→EC differentiation.
Mechanistic Link Between ALK1 and 
BMP9-Enhanced EPC Neovascularization 
in a Mouse Hindlimb Ischemia Model
To assess whether ALK1 is related to EPC function in vivo and 
in vitro, we induced hindlimb ischemia in mice and treated the 
animals with hALK1-Fc. As expected, BMP9 treatment with the 
transplantation of EPCs in the ischemic limbs led to a dramatic 
improvement in hindlimb blood perfusion (Figure 6A and 6B) 
and elevated vessel densities (Figure 6C and 6D). However, 
in hALK1-Fc–treated BMP9/EPCs transplanted into mice, we 
observed decreased blood perfusion (Figure 6A and 6B) and 
vessel density (Figure 6C and 6D). Furthermore, immunofluo-
rescence labeling demonstrated that a greater number of hEPCs 
were incorporated into CD31-positive mouse ECs in the BMP9/
EPC group, but hALK1-Fc treatment reversed this effect and 
resulted in outcomes similar to the EPC group (Figure 6E and 
6F). These findings were consistent with our in vitro data, and 
suggested that the in vivo angiogenic capacity of EPCs is because 
of, at least in part, ALK1 pathway signaling in these cells.
Discussion
In the current study, we determined that BMP9 is a novel regu-
lator of EPC-mediated neovascularization and demonstrated 
Figure 4. Bone morphogenetic protein 9 (BMP9) improves blood flow in ischemic mouse hindlimbs after human endothelial progenitor 
cell (hEPCs)–BMP9 transplantation. A–D, After unilateral hindlimb ischemia surgery, ischemic calf muscles were injected with EPCs alone, 
EPCs plus BMP9 (100 ng), BMP9 alone (100 ng), or vehicle. Representative examples of laser-Doppler images (A) and quantification of 
hindlimb blood flow (B). ###P<0.001, BMP9-treated vs vehicle-injected group; ***P<0.01, BMP9-treated vs hEPC-injected group; n=9 ani-
mals per group. C, Representative figures immunolabeled with antimouse CD31 (red). Scale bar, 50 µm. D, Quantitative analysis of capil-
lary density. ###P<0.001, BMP9-treated vs vehicle-injected group; **P<0.01 BMP9-treated vs EPCs-injected group; n=10 animals per 
group. E–H, After unilateral hindlimb ischemia surgery, ischemic calf muscles were injected with BMP9-primed EPCs. EPCs were primed 
BMP9 (10 ng/mL) for 24 hours, before injection. Representative examples of laser-Doppler images at 28 days (E) and quantification of 
hindlimb blood flow (F). *P<0.05, n=5 animals per group. G, Representative figures immunolabeled with antimouse CD31 (red). Scale bar, 
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that BMP9 significantly increased EPC→EC differentiation 
and the angiogenic activities of EPCs. BMP9 also improved 
neovascularization in a mouse hindlimb ischemia model by 
increasing vessel density and ultimately improving blood 
perfusion. We determined that the effects of BMP9-induced 
EPC neovascularization were mediated by ALK1, which is 
expressed in EPCs. Furthermore, both short- and long-term 
stimulation of BMP9 could induce EPC incorporation into 
neovascular structures, which indicates diverse therapeutic 
applications for patients with ischemic vascular diseases.
Accumulating evidence suggests that EPCs have thera-
peutic potential in promoting the re-endothelialization of 
damaged vessel walls and the neovascularization of isch-
emic tissues.4,13 The contributions of EPCs to neovascular-
ization are thought to be mediated through paracrine effects 
by the secretion of angiogenic cytokines and direct involve-
ment of de novo differentiated ECs after EPC incorporation 
into ischemic tissues.13 Several factors, including VEGF and 
stromal-derived factor-1, have been shown to promote neovas-
cularization by enhancing EPC utility in the ischemic sites in 
addition to the direct angiogenic actions of EPCs.7,8 Although 
the ways and extents to which these molecules affect EPCs 
vary, the recruitment of EPCs to the ischemic site, which 
involves motility and adhesion to the neovascular area, is a 
commonality. Accordingly, the results of the in vitro assays in 
this study demonstrated that BMP9 increases EPC chemotaxis 
and adhesion. Circulating EPCs are mobilized both endog-
enously in response to tissue ischemia and exogenously by 
cytokines in ischemic tissues.4,11 The possibility that cytokines 
could mobilize EPCs has been implied by several previous 
observations. VEGF mobilizes EPCs from BM, and stromal-
derived factor-1 stimulates local accumulation of transplanted 
EPCs, thereby resulting in enhanced neovascularization in a 
mouse hindlimb ischemia model.7,41 Here, we demonstrated 
that BMP9 exerts a chemotactic effect on EPCs in a manner 
similar to that of VEGF. These observations suggested that 
BMP9-mediated signals can enhance EPC recruitment to 
ischemic sites. Multiple integrins have also been implicated 
in EPC mobilization, homing, and differentiation. In par-
ticular, integrin α5β1 is expressed in EPCs and is involved 
in the homing of EPCs to denuded vessels, where it acts as 
a fibronectin receptor.42 Interestingly, stimulation of EPCs 
with BMP9 increased adhesion to fibronectin and HUVECs 
by increasing integrin α5β1 expression. Consequently, local 
BMP9 administration might improve EPC homing to isch-
emic sites by increasing their migration and adhesion. To this 
Figure 5. Bone morphogenetic protein 9 (BMP9) increases endothelial progenitor cell (EPC) incorporation and differentiation into ECs in 
vivo. A, reverse transcriptase-polymerase chain reaction for human GAPDH showing the presence of human cells in mouse ischemic tis-
sues. In vitro cultured human umbilical vein cell (HUVEC)s and human EPC (hEPC) cDNA are positive controls. B and C, The formation of 
capillary networks between CD31-positive human cells (transplanted hEPCs, arrow) and CD31-positive mouse cells (mouse ECs, arrow-
heads) was observed in ischemic limb tissues 1 month after transplantation. B, Transplantation of DiI-acetylated low-density lipoprotein–
labeled hEPCs (red) with BMP9 in ischemic limb. Vasculature was labeled with an anti-CD31 antibody (green), and nuclei were stained 
with DAPI (blue). Scale bars, 20 µm. C, Transplantation of calcein AM–labeled hEPCs (green) with BMP9 in ischemic limb. Vasculature 
was labeled with an anti-CD31 antibody (red), and nuclei were stained with DAPI (blue). Scale bars, 20 µm. D, Calcein AM–labeled hEPCs 
(green) were costained with human nuclear antigen (HNA, blue) and incorporated into the vascular endothelium (red) in the ischemic mus-
cle. Scale bar, 20 µm. E, Transplanted hEPCs were differentiated into ECs that stained with kinase insert domain receptor (KDR). From 
left to right, First through third panels, calcein AM–labeled hEPCs (green) were costained with the human EC marker, KDR (blue), and 
were incorporated into the vascular endothelium (red) in ischemic tissue. Scale bar, 20 µm; fourth panel, a 3-dimensional-reconstructed 
merged confocal image. KDR-positive transplanted hEPCs (arrows) were observed in mouse ECs. Scale bar, 20 µm; fifth panel, an 
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end, we found that intramuscular injections of BMP9 and 
EPCs combined significantly improved blood flow recovery 
and capillary density in ischemic muscle versus the injec-
tion of only EPCs in the mouse hindlimb ischemia model. 
Interestingly, when we administered local injections of mouse 
or human BMP9 only, no improvement was observed. This 
result suggested that BMP9 only affects EPCs and may not be 
sufficient to mobilize EPCs from bone marrow. Nevertheless, 
coadministration of EPCs with BMP9 did lead to improve-
ments. A sufficient number of EPCs were recruited to the local 
BMP9 injection sites and were synchronized by activation of 
adhesion molecules in the integrin family.
An alternative approach involves priming, which is the 
short-term, protein-based, ex vivo stimulation of EPCs before 
therapeutic injection. EPC pretreatment with mobilizing 
factors initiates an activation program within EPCs; thus, the 
therapeutic issue of EPC engraftment might circumvent the 
insufficient cell numbers and low efficiency of EPC incorpo-
ration.9,12 We demonstrated that BMP9-primed EPCs repaired 
mouse limb ischemia by increasing capillary density, which 
subsequently improved blood flow. This result was further 
supported by our in vitro observation that priming EPCs 
with BMP9 increased the number of EPCs incorporated into 
tubules in Matrigel angiogenesis assays. Thus, BMP9 priming 
could enable EPCs to overcome the limitation of the duration 
of their effects on EPC-mediated neovascularization. Overall, 
we optimized the conditions of EPC-based therapy using co- 
and pretreatment with BMP9, which facilitated the multistep 
process of EPC recruitment, adhesion, and incorporation into 
vasculature.
Figure 6. Bone morphogenetic protein 9 (BMP9)–induced endothelial progenitor cell (EPC) neovascularization is regulated by activin 
receptor-like kinase 1 (ALK1) in the mouse hindlimb ischemia model. After unilateral hindlimb ischemia surgery, ischemic calf muscles 
were injected with EPCs with or without BMP9 and hFc-ALK1. Representative examples of laser-Doppler images (A) and quantification 
of hindlimb blood flow (B). **P<0.01, *P<0.05, BMP9-treated EPCs vs EPCs group; #P<0.05, BMP9-treated EPCs vs hFc-ALK1-treated 
EPCs group; n=5 animals per group. C, Representative figures of antimouse CD31 immunolabeling (red). Scale bar, 50 µm. D, Quantita-
tive analysis of capillary density. ***P<0.001, ##P<0.01, n=7 animals per group. E, Confocal analysis showed that Calcein AM–labeled 
EPCs (green) were incorporated into the vascular endothelium (red) in ischemic muscle. Scale bar, 50 µm. F, Bar graph showing the rela-
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The order of signals required to initiate EPC differentia-
tion to ECs and to activate EPCs to participate in neovascular-
ization remains unclear. To address the fundamental questions 
on EPC biology and the associated underlying molecular 
mechanisms, global gene expression profiling of cord blood–
derived EPCs was performed to identify genes involved 
in EPC differentiation. The resulting profiles indicated a 
requirement for TGF-β signaling in EPC differentiation and 
provided a comprehensive understanding of EPC molecular 
mechanisms, which could decrease the associated risks and 
increase the efficacy of EPC-based therapies. Previous stud-
ies have demonstrated that TGF-β family members function 
in the maintenance and differentiation of ES, somatic stem 
cells, and cancer stem cells.17,18 The activation of the TGF-β/
activin/nodal branch through Smad2/3 signaling is important 
for human ES to retain their undifferentiated state, whereas 
the differentiation of human ES results in increased Smad1/5 
phosphorylation and localization to the nucleus.17 Combined 
with our results, which described Smad1/5 phosphorylation in 
EPCs after BMP9 treatment, the existing data suggest a com-
pelling role for Smad 1/5 signaling in the differentiation of 
hEPCs and human ES.
TGF-β signaling is highly regulated to control the balance 
between activating and resting signals during angiogenesis 
in ECs.20 Recent studies have demonstrated that TGF-β can 
bind ALK1 and ALK5, which are 2 distinct type 1 receptors 
that exert opposite effects in ECs.20,21 In accord with previ-
ous studies, ALK1 and ALK5 expression levels exhibited 
opposite patterns in our system as the level of ALK1 was 
increased, whereas ALK5 decreased during EPC→EC dif-
ferentiation. The ratio of ALK5:ALK1 on ECs is important 
for determining whether the condition of the endothelium is 
activated or quiescent. ALK1 is upregulated at sites of active 
angiogenesis during mouse embryogenesis and stimulates EC 
migration and proliferation. ALK5, however, is more widely 
expressed, and inhibits EC migration and proliferation.44 
Similarly, we examined the expression of ALK1 and ALK5 
during EPC→EC differentiation and found that the activa-
tion of ALK1 induced EPC→EC differentiation, EPC adhe-
sion, and migration. Increasing evidence indicates that BMP9 
binds ALK1 with high affinity, and that ALK1 is abundantly 
expressed in the vascular system, including in ECs.22 This 
report describes ALK1 expression on EPCs and demonstrates 
both in vitro and in vivo that BMP9 can activate EPCs through 
ALK1. Defective ALK1 signaling reduces EPC differentia-
tion and angiogenic functional abilities, even in the presence 
of BMP9 stimulation. CA-ALK1 expression after lentiviral 
transfection significantly accelerated EPC→EC differentia-
tion versus dominant-negative ALK1 and mock transfectants. 
Recently, soluble ALK1 was used to block circulating BMP9. 
The hALK1-Fc conjugate binds to both BMP9 and BMP10, 
but not to other TGF-β family members (ie, TGF-β1, TGF-
β2, and TGF-β3), and exhibits a powerful antiangiogenic 
ability that blocks vascularization in tumor angiogenesis.43,45 
In accord with previous results, hALK1-Fc/BMP9 coadmin-
istration blocked Smad1/5 phosphorylation and decreased 
both tube formation and the number of EPCs incorporated 
into neovessel-like structures in Matrigel angiogenesis assays. 
Likewise, tube formation induced by BMP9-primed EPCs was 
reduced by pretreatment with hALK1-Fc. We also observed 
that BMP9-induced EPC neovascularization in ischemic limbs 
was ALK1 dependent. Thus, we think that the interaction of 
BMP9 and ALK1 is specifically involved in EPC-based neo-
vascularization, and that the BMP9/ALK1-mediated signal 
is a novel molecular target for the modulation of EPC-based 
therapeutic neovascularization.
Knowledge of the cues that specify cell types is impor-
tant because the introduction of inappropriate cells into organs 
during stem/progenitor cell-based therapies decreases trans-
plantation safety and efficacy. For instance, the unnecessary 
introduction of hematopoietic cells results in undesired side 
effects, such as the formation of dilated hemorrhage-prone 
vessels and edema.13,46 In our mouse hindlimb ischemia 
model, the vasculature-incorporated EPCs differentiated and 
acquired endothelial phenotypes, including KDR expression. 
This observation suggested that EPCs not only integrated into 
blood vessels but also differentiated into mature, functional 
ECs after BMP9 stimulation. There is still a discrepancy for 
isolation and definition of true EPCs. Interestingly, after the 
repeated washing process of MNC cultures, we found that 
umbilical cord blood–derived adherent cells on fibronectin-
coated dish did not have CD45 expression. On the contrary, we 
have collected cells from the supernatant and found cells with 
high CD45 expression. Identical results were obtained with 
EPCs on collagen-coated dish. CD45high cells adhered weakly 
to fibronectin or collagen-coated culture dish and washed out 
by soup. Therefore, CD45− functional EPCs remained adher-
ent. These umbilical cord blood–derived CD45- cells gener-
ated endothelial outgrowth cells with identical morphological 
and phenotypic characteristics as described by Timmermans 
et al.47 Endothelial outgrowth cells derived from the true EPC 
contribute more directly to neovascularization.48 Overall, 
true EPCs transplantation with BMP9 is expected to improve 
safety and efficacy of cell therapy.
In summary, our results delineated relationships involved 
in BMP9/ALK1, EPC→EC differentiation, and EPC-mediated 
neovascularization. It is debatable whether BMP9 functions 
as an angiogenic factor43,49 or as an antiangiogenic factor in 
ECs.24,39 However, our results extended the angiogenic role of 
BMP9 through ALK1 signaling in EPC biology, and demon-
strated that BMP9 improves angiogenesis by increasing EPC 
functional incorporation into developing neovasculature and 
enhances vasculogenesis by inducing EPC→EC differentia-
tion. Several studies involving animal models have shown that 
EPCs that differentiated into mature ECs accounted for ≈25% 
of ECs in newly formed vessels.50,51 However, we suggest 
that BMP9 could improve this low efficacy by promoting the 
adhesion of integrin-induced EPCs to injured vascular sites, 
incorporation of EPCs into vessels, and the differentiation of 
EPCs into functional ECs, all of which eventually accelerate 
neovascularization. In addition, both short- and long-term 
administration of BMP9 could have clinical implications 
for EPC-mediated neovascularization. Accordingly, BMP9/
ALK1 should be considered a potential molecular target for 
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Peripheral arterial occlusive disease can lead to critical limb ischemia, which causes gangrene and eventually necessitates amputation of the 
limb. Therefore, more effective revascularization strategies that stimulate blood vessel growth are necessary to treat patients with critical 
limb ischemia. Given the angiogenic roles of EPCs in pathophysiological conditions, cell therapy with EPCs has been used to treat vascular 
diseases such as limb ischemia. Here, we found that BMP9 stimulated multiple steps of EPC homing and differentiation in vitro and promoted 
both EPC incorporation into the neovascular area and differentiation into EC, which resulted in enhanced angiogenesis in hindlimb ischemia. 
The effects of BMP9 are primarily because of their binding of ALK1 expressed on EPCs and the blockage of ALK1 signaling impaired neo-
vascularization. Thus, our findings suggested that the use of BMP9 might be significant in EPC-based neovascularization strategies used to 
treat ischemic vascular diseases.
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